GNPX Stock Summary and Trading Ideas (Genprex | NASDAQ:GNPX)

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Genprex trades on the NASDAQ stock market under the symbol GNPX.

As of March 23, 2026, GNPX stock price climbed to $1.92 with 142,638 million shares trading.

GNPX has a beta of -0.47, meaning it tends to be less sensitive to market movements. GNPX has a correlation of 0.00 to the broad based SPY ETF.

GNPX has a market cap of $4.36 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, GNPX traded as high as $2,300.00 and as low as $1.71.

The top ETF exchange traded funds that GNPX belongs to (by Net Assets): VXF.

GNPX has underperformed the market in the last year with a return of -89.8%, while the SPY ETF gained +18.4%. In the last 3 month period, GNPX fell short of the market, returning -9.9%, while SPY returned -3.0%. However, in the most recent 2 weeks GNPX has outperformed the stock market by returning -1.5%, while SPY returned -1.8%.

GNPX support price is $1.75 and resistance is $2.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GNPX shares will trade within this expected range on the day.